Metabolomics and Biomarkers for Drug Discovery

Metabolomics and biomarkers are increasingly used in drug discovery and development, and are applied to personalized medicine. Progress in these research areas has increased our understanding of disease pathology and improved therapeutic strategies for many diseases with unmet challenges. Further ad...

Descripción completa

Detalles Bibliográficos
Autor principal: Yeung, Pollen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876001/
https://www.ncbi.nlm.nih.gov/pubmed/29385049
http://dx.doi.org/10.3390/metabo8010011
_version_ 1783310445104332800
author Yeung, Pollen K.
author_facet Yeung, Pollen K.
author_sort Yeung, Pollen K.
collection PubMed
description Metabolomics and biomarkers are increasingly used in drug discovery and development, and are applied to personalized medicine. Progress in these research areas has increased our understanding of disease pathology and improved therapeutic strategies for many diseases with unmet challenges. Further advances will ultimately result in the development of better drugs and breakthrough therapies, which will benefit millions of patients suffering from chronic and life-threatening diseases worldwide.
format Online
Article
Text
id pubmed-5876001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58760012018-03-30 Metabolomics and Biomarkers for Drug Discovery Yeung, Pollen K. Metabolites Editorial Metabolomics and biomarkers are increasingly used in drug discovery and development, and are applied to personalized medicine. Progress in these research areas has increased our understanding of disease pathology and improved therapeutic strategies for many diseases with unmet challenges. Further advances will ultimately result in the development of better drugs and breakthrough therapies, which will benefit millions of patients suffering from chronic and life-threatening diseases worldwide. MDPI 2018-01-31 /pmc/articles/PMC5876001/ /pubmed/29385049 http://dx.doi.org/10.3390/metabo8010011 Text en © 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Yeung, Pollen K.
Metabolomics and Biomarkers for Drug Discovery
title Metabolomics and Biomarkers for Drug Discovery
title_full Metabolomics and Biomarkers for Drug Discovery
title_fullStr Metabolomics and Biomarkers for Drug Discovery
title_full_unstemmed Metabolomics and Biomarkers for Drug Discovery
title_short Metabolomics and Biomarkers for Drug Discovery
title_sort metabolomics and biomarkers for drug discovery
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876001/
https://www.ncbi.nlm.nih.gov/pubmed/29385049
http://dx.doi.org/10.3390/metabo8010011
work_keys_str_mv AT yeungpollenk metabolomicsandbiomarkersfordrugdiscovery

Ejemplares similares